Version May 2024
Bowel cleansing:
CoLyte, GaviLyte-C, GaviLyte-G, GaviLyte-N, GoLYTELY, NuLYTELY, TriLyte:
Oral: 240 mL (8 oz) every 10 minutes until 4 L are consumed or the rectal effluent is clear; rapid drinking of each portion is preferred to drinking small amounts continuously
Nasogastric: 20 to 30 mL/minute (1.2 to 1.8 L/hour) until 4 L are administered or the rectal effluent is clear
MoviPrep: Oral: Administer 2 L total with an additional 1 L of clear fluid prior to colonoscopy as follows:
Split dose (2 day regimen) (preferred method):
Dose 1: Evening before colonoscopy (10 to 12 hours before dose 2): 240 mL (8 oz) every 15 minutes until 1 L (entire contents of container) is consumed. Then fill container with 480 mL (16 oz) of clear liquid and consume prior to going to bed.
Dose 2: On the morning of the colonoscopy (beginning at least 3.5 hours prior to procedure): 240 mL (8 oz) every 15 minutes until 1 L (entire contents of container) is consumed. Then fill container with 480 mL (16 oz) of clear liquid and consume at least 2 hours before the procedure.
Evening only dose (1 day regimen) (alternate method):
Dose 1: Evening before colonoscopy (at least 3.5 hours before bedtime): 240 mL (8 oz) every 15 minutes until 1 L (entire contents of container) is consumed
Dose 2: ~90 minutes after starting dose 1: 240 mL (8 oz) every 15 minutes until 1 L (entire contents of container) is consumed. Then fill container with 1 L (32 oz) of clear liquid and consume all of the liquid prior to going to bed.
Plenvu: Oral: Note: Two doses are required; may use either a “Two-Day” or “One-Day” dosing regimen:
Split dose (2 day regimen):
Dose 1: Evening before colonoscopy (~4 pm to 8 pm): 480 mL (16 oz) consumed over 30 minutes (entire contents of container). Then fill container with 480 mL (16 oz) of clear liquid and consume all of the liquid over next 30 minutes; consume additional clear liquids during the evening.
Dose 2: On the morning of the colonoscopy (~4 am and 8 am [~12 hours after the start of Dose 1]): 480 mL (16 oz) consumed over 30 minutes (entire contents of container). Then fill container with 480 mL (16 oz) of clear liquid and consume all of the liquid over next 30 minutes; consume additional water or clear liquids up to 2 hours before procedure.
One-day only morning dose (1 day regimen):
Dose 1: Morning of colonoscopy (~3 am and 7 am): 480 mL (16 oz) consumed over 30 minutes (entire contents of container). Then fill container with 480 mL (16 oz) of clear liquid and consume all of the liquid over next 30 minutes.
Dose 2: Morning of colonoscopy (minimum of 2 hours after start of dose 1): 480 mL (16 oz) consumed over 30 minutes (entire contents of container). Then fill container with 480 mL (16 oz) of clear liquid and consume all of liquid over next 30 minutes; consume additional water or clear liquids up to 2 hours before procedure.
Suflave: Oral: Note: Two doses are required for a complete dose.
Split dose (2 day regimen):
Dose 1: Early evening before colonoscopy: 240 mL (8 oz) every 15 minutes until entire contents of container is consumed. Then consume an additional 480 mL (16 oz) of water during the evening.
Dose 2: On the morning of the colonoscopy (beginning 5 to 8 hours prior to procedure and at least 4 hours from starting the first dose): 240 mL (8 oz) every 15 minutes until entire contents of container is consumed. Then consume an additional 480 mL (16 oz) of water during the morning at least 2 hours before the procedure.
Whole bowel irrigation for toxic ingestion (off-label use): Nasogastric: 1,500 to 2,000 mL/hour until the rectal effluent is clear (Ref). Note: Continue treatment at least until the rectal effluent is clear; treatment duration may be extended based on corroborative evidence of continued presence of poisons in the GI tract as determined by radiographic means or the presence of the poison in the effluent (Ref).
Do sage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
There are no dosage adjustments provided in the manufacturer's labeling. Use with caution due to risk of fluid and electrolyte abnormalities.
There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).
Refer to adult dosing.
(For additional information see "Polyethylene glycol and electrolyte solution: Pediatric drug information")
Bowel cleansing: Limited data available:
Note: To prevent excessive fluid and electrolyte changes, use only products containing supplemental electrolytes for bowel cleansing. Patient should fast at least 2 hours (preferably 3 to 4 hours) prior to ingestion.
Infants ≥6 months, Children, and Adolescents: GaviLyte-N, NuLYTELY, and TriLyte: Oral, nasogastric: 25 mL/kg/hour until rectal effluent is clear (usually in ~4 hours). One study used 40 mL/kg/hour intermittently by mouth or continuously by nasogastric drip in patients ≥18 months (Ref). Although not FDA approved for pediatric patients, other preparations have been used in pediatric studies: Colyte, GoLYTELY (Ref).
Constipation or fecal impaction: Limited data available:
Outpatient therapy: Children >2 years and Adolescents: Oral: 20 mL/kg/hour up to a maximum dose of 1 L/hour for 4 hours/day for 2 days (Ref).
Inpatient therapy: Children and Adolescents: Oral, Nasogastric: 25 to 40 mL/kg/hour up to a maximum dose of 2 L/hour if tolerated; continue until stools completely liquid (ideally clear in color). May decrease dose to half of the initial rate if patient does not tolerate volume (Ref).
Whole bowel irrigation for toxic ingestion: Limited data available (Ref):
Note: Whole bowel irrigation with polyethylene glycol-electrolyte solution is not recommended routinely in the management of poisoned patients; use has not been validated in controlled studies and in some cases may complicate patient management (eg, hemodynamically unstable) (Ref).
Infants ≥9 months and Children <6 years: Nasogastric: 500 mL/hour until rectal effluent is clear.
Children ≥6 years: Nasogastric: 1,000 mL/hour until rectal effluent is clear.
Adolescents: Nasogastric: 1,500 to 2,000 mL/hour until rectal effluent is clear.
Note: Continue treatment at least until the rectal effluent is clear; treatment duration may be extended based on corroborative evidence of continued presence of poisons in the GI tract as determined by radiographic means or the presence of the poison in the effluent.
There are no dosage adjustments provided in the manufacturer's labeling (not studied). Use with caution due to risk of fluid and electrolyte abnormalities.
There are no dosage adjustments provided in the manufacturer's labeling (not studied).
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
>10%:
Endocrine & metabolic: Hypermagnesemia (11% to 12%), increased thirst (evening only, full dose: 47%)
Gastrointestinal: Abdominal distention (full dose: 1% to 60%; split dose: 1%), abdominal pain (≤39%; split dose: ≤13%), anorectal pain (≤52%), bloating (≤50%), epigastric fullness (≤50%), hunger (evening only, full dose: 30%), nausea (≤50%; split dose: 3% to 14%)
Nervous system: Malaise (18% to 27%), rigors (evening only, full dose: 34%), sleep disorder (evening only, full dose: 35%)
1% to 10%:
Cardiovascular: Hypertension (1% to 2%)
Endocrine & metabolic: Dehydration (4%), electrolyte disorder (1% to 2%)
Gastrointestinal: Abdominal distress (≤3%), dyspepsia (split dose: 3%), gastritis (split dose: 1%), hiatal hernia (split dose: 1%), upper abdominal pain (6%), vomiting (4% to 8%)
Nervous system: Dizziness (evening only, full dose: 7%), fatigue (split dose: 2%), headache (1% to 3%)
Renal: Decreased estimated GFR (eGFR: 1% to 2%), increased serum creatinine (1% to 2%)
Respiratory: Nasopharyngitis (split dose: 1%)
Frequency not defined:
Endocrine & metabolic: Decreased serum bicarbonate, hyperchloremia, increased serum calcium, increased serum phosphate, increased serum sodium, increased uric acid (serum), serum hyperosmolarity
Gastrointestinal: Abdominal cramps
Nervous system: Tightness in chest or throat
Renal: Decreased creatinine clearance, increased blood urea nitrogen
<1%, postmarketing, and/or case reports: Acute pulmonary edema, anaphylactic shock, anaphylaxis, angioedema, asthenia, asystole, atrial fibrillation, cardiac arrhythmia, chills, dermatitis, drowsiness, dyspnea, esophageal perforation, facial edema, fever, gastroesophageal reflux disease, generalized ache or pain, hot flash, hypersensitivity reaction, hypokalemia (children), increased liver enzymes, lip edema, Mallory-Weiss syndrome, migraine, pain, palpitations, perianal skin irritation, peripheral edema, pharyngeal edema, pruritus, pulmonary aspiration, pulmonary edema (>60 years old), renal failure syndrome, renal insufficiency, rhinorrhea, seizure, sinus tachycardia, skin rash, syncope, tachycardia, tongue edema, tremor, upper gastrointestinal hemorrhage, urticaria
Hypersensitivity to polyethylene glycol-electrolyte solution or any component of the formulation; ileus, GI obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon.
Additional contraindications may include hemodynamic instability, clinically significant GI hemorrhage, uncontrollable or intractable vomiting, or an unprotected compromised airway (AACT/EAPCCT 2004; Thanacoody 2015).
Canadian labeling: Additional contraindications (not in US labeling): Acute surgical abdominal conditions (eg, acute appendicitis, diverticulitis); unconscious patients.
Concerns related to adverse effects:
• Arrhythmias: Serious arrhythmias have been reported (rarely) with the use of ionic osmotic laxative products (predominantly in patients with underlying cardiac risk factors and electrolyte disturbances). Use with caution in patients who may be at risk of cardiac arrhythmias (eg, patients with a history of prolonged QT, uncontrolled arrhythmias, recent MI, unstable angina, heart failure, cardiomyopathy, or electrolyte imbalance); consider pre-dose and post-colonoscopy ECGs in patients at risk of serious cardiac arrhythmias.
• Fluid and electrolyte abnormalities: May cause fluid and electrolyte disturbances, which can lead to arrhythmias, seizures, and renal impairment. Correct fluid and electrolyte abnormalities before treatment. Advise patients to maintain adequate hydration before, during, and after treatment. Use with caution in patients taking concomitant medications that may increase the risk of electrolyte abnormalities (eg, diuretics, ACE inhibitors, ARBs). If patient becomes dehydrated or experiences significant vomiting after treatment, consider post-colonoscopy lab tests (electrolytes, creatinine, and BUN).
• Hypersensitivity: Serious hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria, and pruritus may occur; discontinue use and seek medical care if hypersensitivity reaction occurs.
• Ischemic colitis/mucosal aphthous ulcerations: Cases of ischemic colitis have been reported; concomitant use of stimulant laxatives may increase the risk and is not recommended. The potential for mucosal aphthous ulcerations as a result of the bowel preparation should be considered, especially when evaluating colonoscopy results in patients with known or suspected inflammatory bowel disease.
• Seizures: Generalized tonic-clonic seizures and/or loss of consciousness have occurred rarely in patients with no prior history of seizures. Seizures were associated with electrolyte abnormalities (eg, hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia) and low serum osmolality and resolved with the correction of fluid and electrolyte abnormalities. Use with caution in patients with a history of seizures or who are at an increased risk of seizures (eg, concomitant administration of medications that lower the seizures threshold, patients withdrawing from alcohol or benzodiazepines) and in patients with known or suspected hyponatremia or low serum osmolality.
Disease-related concerns:
• GI obstruction/perforation: If GI obstruction or perforation is suspected, perform appropriate diagnostic studies to rule out these conditions before administration.
• Impaired gag reflex: Observe unconscious or semiconscious patients with impaired gag reflex, other swallowing abnormalities, or those who are otherwise prone to regurgitation or aspiration during administration. Use with caution, especially when administered via NG tube. Patients with an unprotected airway are at risk. Protect the airway and keep the head of the bed elevated >45° (AACT/EAPCCT 2004).
• Renal impairment: Use with caution in patients with renal impairment and/or in patients taking medications that may adversely affect renal function (eg, diuretics, NSAIDs, ACE inhibitors, ARBs); these patients should remain adequately hydrated before, during, and after use; consider preadministration and postadministration lab tests (electrolytes, creatinine, BUN).
• Ulcerative colitis: Use with caution in patients with severe ulcerative colitis.
Special populations:
• Body packing: Patients who present following ingestion of packets of illicit drugs ("body packers") may require a longer duration of decontamination secondary to the presence of retained packets.
• Older adult: Use with caution in patients >60 years of age; serious adverse events have been reported (eg, asystole, esophageal perforation, chest infiltration following vomiting and aspiration, Mallory-Weiss tear with GI bleeding, pulmonary edema with sudden dyspnea).
• Pediatric: Use in patients <2 years of age may result in hypoglycemia, dehydration, and hypokalemia; use with caution and monitor closely.
Dosage form specific issues:
• MoviPrep, Plenvu: Use with caution in patients with G6PD deficiency (especially patients with an active infection, history of hemolysis, or taking concomitant medications known to precipitate hemolytic reactions) due to the presence of sodium ascorbate and ascorbic acid in the formulation.
• Phenylalanine: MoviPrep, Plenvu: Contains phenylalanine; use with caution in patients with phenylketonuria (PKU).
Other warnings/precautions:
• Appropriate use: If a patient develops severe bloating, distention or abdominal pain during administration, slow the rate of administration or temporarily discontinue use until the symptoms subside. Correct electrolyte abnormalities in patients prior to use. No additional ingredients or flavors (other than the flavor packets provided) should be added to the polyethylene glycol-electrolyte solution. Do not combine with starch-based thickeners; choking and potential aspiration may occur.
- Poisoned patients: Whole bowel irrigation (WBI) with polyethylene glycol-electrolyte solution is not recommended routinely in the management of poisoned patients; its use has not been validated in controlled studies. In some cases, it may complicate patient management (Cumpston 2010).
The effects of long-term use or large doses of polyethylene glycol in children are unknown. The FDA has received reports of metabolic acidosis (with and without anion gap) and neuropsychiatric events in children taking polyethylene glycol products; however, direct causality with the drug has not been established. Neuropsychiatric adverse events reported may include seizures, tremors, tics, headache, anxiety, lethargy, sedation, aggression, rages, obsessive-compulsive behaviors (including repetitive chewing and sucking), paranoia, and mood swings. Studies are underway to define the metabolic processes and pathways of polyethylene glycol (and any metabolites) in pediatric patients and to determine gastrointestinal absorption properties if any (FDA 2013). As of 2014, the FDA decided no action was necessary based upon available data (FDA 2014). Monitor pediatric patients closely for signs of metabolic acidosis or neuropsychiatric changes.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Powder for Solution, Oral:
Colyte: PEG 3350 227.1 g, sodium sulfate 21.5 g, sodium bicarbonate 6.36 g, sodium chloride 5.53 g, and potassium chloride 2.82 g (3785 mL [DSC]) [supplied with cherry, lemon lime, and orange flavor packs]
Colyte: PEG 3350 240 g, sodium sulfate 22.72 g, sodium bicarbonate 6.72 g, sodium chloride 5.84 g, and potassium chloride 2.98 g (4000 mL) [supplied with cherry, citrus berry, lemon lime, orange, and pineapple flavor packs]
Gavilyte-C: PEG 3350 240g, sodium sulfate 22.72 g, sodium bicarbonate 6.72 g, sodium chloride 5.84 g, and potassium chloride 2.98 g (4000 mL) [supplied with lemon flavor packet]
Gavilyte-G: PEG 3350 236 g, sodium sulfate 22.74 g, sodium bicarbonate 6.74 g, sodium chloride 5.86 g, and potassium chloride 2.97 g (4000 mL) [supplied with lemon flavor packet]
GaviLyte-N: PEG 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL) [supplied with lemon flavor packet]
GoLYTELY: PEG 3350 227.1 g, sodium sulfate 21.5 g, sodium bicarbonate 6.36 g, sodium chloride 5.53 g, and potassium chloride 2.82 g per packet (1s) [regular flavor; makes 1 gallon of solution after mixing]
GoLYTELY: PEG 3350 236 g, sodium sulfate 22.74 g, sodium bicarbonate 6.74 g, sodium chloride 5.86 g, and potassium chloride 2.97 g (4000 mL) [regular and pineapple flavor]
MoviPrep: Pouch A: PEG 3350 100g, sodium sulfate 7.5 g, sodium chloride 2.69 g, potassium chloride 1.02 g; Pouch B: Ascorbic acid 4.7 g, sodium ascorbate 5.9 g (1000 mL) [contains phenylalanine 131 mg/treatment; lemon flavor; packaged with 2 of Pouch A and 2 of Pouch B in carton and a disposable reconstitution container]
NuLYTELY: PEG 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL [DSC]) [supplied with cherry, lemon-lime, orange, and pineapple flavor packs]
Plenvu: Dose 1: PEG 3350 100 g, sodium sulfate 9 g, sodium chloride 2 g, potassium chloride 1 g [mango flavor; makes 473 mL of solution after mixing]; Dose 2, Pouch A: PEG 3350 40 g, sodium chloride 3.2 g, potassium chloride 1.2 g; Dose 2, Pouch B: sodium ascorbate 48.11 g, ascorbic acid 7.54 g [contains phenylalanine 491 mg/treatment; fruit punch flavor; makes 473 mL of solution after mixing]
TriLyte: PEG 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL [DSC]) [supplied with cherry, citrus berry, lemon lime, orange, and pineapple flavor packs]
Generic: PEG 3350 240 g, sodium sulfate 22.72 g, sodium bicarbonate 6.72 g, sodium chloride 5.84 g, and potassium chloride 2.98 g (4000 mL [DSC]); PEG 3350 236 g, sodium sulfate 22.74 g, sodium bicarbonate 6.74 g, sodium chloride 5.86 g, and potassium chloride 2.97 g (4000 mL); PEG 3350 240 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL); PEG 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL)
Yes
Solution (reconstituted) (GaviLyte-C Oral)
240 g (per mL): $0.01
Solution (reconstituted) (GaviLyte-G Oral)
236 g (per mL): $0.01
Solution (reconstituted) (Golytely Oral)
236 g (per mL): $0.01
Solution (reconstituted) (MoviPrep Oral)
100 g (per each): $151.06
Solution (reconstituted) (PEG 3350-KCl-Na Bicarb-NaCl Oral)
420 g (per mL): $0.01 - $0.02
Solution (reconstituted) (PEG-KCl-NaCl-NaSulf-Na Asc-C Oral)
100 g (per each): $127.72
Solution (reconstituted) (Plenvu Oral)
140 g (per each): $56.61
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Oral: Rapid drinking of each portion is preferred to drinking small amounts continuously. No additional ingredients or flavors (other than the flavor packets provided) should be added to the polyethylene glycol-electrolyte solution; do not take other laxatives, eat (including foods with pulp) or drink alcohol, milk, or anything colored red or purple. Chilling the solution may improve palatability; administration of a chilled solution is not recommended in infants. Other additional measures that may improve tolerability include drinking the solution through a straw or sucking on lemon slices or sugar-free menthol candy drops (Ref). If severe abdominal discomfort or distention occurs, stop or slow the rate of drinking solution temporarily until symptoms diminish. Oral medications should not be administered within 1 hour of start of therapy; for Suflave, administer tetracycline or fluoroquinolone antibiotics, iron, digoxin, chlorpromazine, or penicillamine at least 2 hours before or 6 hours after each dose. Refer to manufacturer's labeling for additional information.
Nasogastric administration: CoLyte, GaviLyte-C, GaviLyte-G, GaviLyte-N, GoLYTELY, NuLYTELY, TriLyte: The solution may be administered via nasogastric tube for bowel cleansing and whole bowel irrigation (preferred route; off-label use) in patients who are unwilling or unable to drink the solution.
Oral: For bowel cleansing, no solid foods for 2 to 4 hours prior to initiation of therapy; rapid drinking is preferred to drinking small amounts continuously; chilled solution often more palatable, but not recommended for infants; refrigerate reconstituted solution when not in use; do not add ingredients as flavorings before use; discard any unused portion. The solution may be administered via nasogastric tube for bowel cleansing in patients who are unwilling or unable to drink the solution; for whole bowel irrigation for toxic ingestions, nasogastric tube administration is preferred.
An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:
GoLYTELY: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019011s033lbl.pdf#page=9
MoviPrep: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021881s023lbl.pdf#page=13
NuLYTELY: https://www.fda.gov/media/86759/download
Plenvu: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209381s013lbl.pdf#page=18
Bowel cleansing: Bowel cleansing prior to colonoscopy or barium enema X-ray examination
Whole bowel irrigation for toxic ingestions
GoLYTELY may be confused with NuLYTELY
Polyethylene glycol-electrolyte solution may be confused with polyethylene glycol 3350, propylene glycol
TriLyte may be confused with TriLipix
Polyethylene glycol 3350 may be confused with polyethylene glycol 4000 [international markets]
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.
Agents With Seizure Threshold Lowering Potential: May enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. Risk C: Monitor therapy
Angiotensin II Receptor Blockers: May enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. Risk C: Monitor therapy
Angiotensin-Converting Enzyme Inhibitors: May enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. Risk C: Monitor therapy
ChlorproMAZINE: May enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. Polyethylene Glycol-Electrolyte Solution may decrease the absorption of ChlorproMAZINE. Management: Give oral chlorpromazine at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation. Monitor for seizures. Risk D: Consider therapy modification
Dichlorphenamide: Laxatives may enhance the hypokalemic effect of Dichlorphenamide. Risk C: Monitor therapy
Digoxin: Polyethylene Glycol-Electrolyte Solution may decrease the absorption of Digoxin. Management: Give oral digoxin at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation. Risk D: Consider therapy modification
Diuretics: May enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. Risk C: Monitor therapy
Iron Preparations: Polyethylene Glycol-Electrolyte Solution may decrease the absorption of Iron Preparations. Management: Give oral iron products at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation. Risk D: Consider therapy modification
Laxatives (Stimulant): May enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of colonic mucosal aphthous ulcerations may be increased. Management: Consider avoiding this combination due to a potential for increased risk of colonic mucosal aphthous ulcerations. Risk D: Consider therapy modification
Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. Risk C: Monitor therapy
PenicillAMINE: Polyethylene Glycol-Electrolyte Solution may decrease the absorption of PenicillAMINE. Management: Give penicillamine at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation. Risk D: Consider therapy modification
Quinolones: Polyethylene Glycol-Electrolyte Solution may decrease the absorption of Quinolones. Management: Give oral quinolones at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation. Risk D: Consider therapy modification
Tetracyclines: Polyethylene Glycol-Electrolyte Solution may decrease the absorption of Tetracyclines. Management: Give oral tetracyclines at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation. Risk D: Consider therapy modification
Information related to the use of polyethylene glycol-electrolyte solution in pregnancy is limited (Neri 2004). Colonoscopy in pregnant women is generally reserved for strong indications or life-threatening emergencies; elective procedures should be delayed until after delivery (Gomes 2018; Siddiqui 2006).
It is not known if polyethylene glycol-electrolyte solution is present in breast milk.
According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.
CoLyte, GaviLyte-C, GaviLyte-G, GaviLyte-N, GoLYTELY, NuLYTELY, TriLyte: Ideally, the patient should fast for ~3 to 4 hours prior to administration, but in no case should solid food be given for at least 2 hours before the solution is given. Some products contain aspartame which is metabolized to phenylalanine. Patients receiving GaviLyte-G or GoLYTELY may consume a light breakfast at least 2 hours before solution is given on the day before the procedure.
MoviPrep: Patient should not eat solid food from start of solution administration until after colonoscopy. Patient may have clear liquid soup/plain yogurt for dinner; finish at least 1 hour before start of colon prep. Contains phenylalanine.
Plenvu: Patient should not eat solid food from start of solution administration until after colonoscopy. For the 2-day split-dosing regimen, the day before the procedure the patient may have a light breakfast followed by a light lunch which must be completed 3 hours before start of colon prep. For the 1-day morning dosing regimen, the day before the procedure the patient may have a light breakfast, followed by a light lunch, and clear broth soup and/or plain yogurt for dinner all completed by ~8 pm. Patient may have clear liquids up to 2 hours before procedure. Contains phenylalanine.
Suflave: Patient should not eat solid food from start of solution administration until after colonoscopy. The day before the procedure the patient may have a low residue light breakfast (eg, white bread, biscuits, muffins [no wheat], cornflakes, eggs, cream of wheat, grits, yogurt, cottage cheese, coffee, tea, juice [without pulp], fruit [no skin or seeds]). Patient may have clear liquids (eg, water, fruit juice [without pulp], lemonade, plain coffee, plain tea, chicken broth, plain gelatin) up to 2 hours before procedure.
BUN, creatinine, electrolytes (at baseline and postcolonoscopy in patients with renal impairment or as clinically indicated); serum glucose, urine osmolality; ECG (at baseline and postcolonoscopy in patients at risk for serious cardiovascular arrhythmias); children <2 years of age should be monitored for hypoglycemia, dehydration, hypokalemia.
Whole bowel irrigation (off-label use) (AACT/EAPCCT 2004; Thanacoody 2014): Rectal effluent (continue until clear or the poison is completely removed).
Induces catharsis by strong electrolyte and osmotic effects. When used for whole bowel irrigation, polyethylene glycol-electrolyte solution cleanses the bowel to potentially reduce drug absorption from the GI tract.
Onset of effect: Oral: ~1 to 2 hours
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
